Fate Therapeutics (NASDAQ:FATE – Free Report) had its target price trimmed by Wells Fargo & Company from $5.00 to $4.00 in a ...

Proficio Capital Partners LLC bought a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the ...

Stevanato's 2024 revenue hits €1.1B, driven by biopharma growth! Discover how facility expansions & rising demand are transforming their market impact.

Reivi Dela Cruz was only four years old when he was diagnosed with Neurofibromatosis Type 1 (NF1), a genetic condition that causes tumors (neurofibromas, which are usually non-cancerous) to grow on or ...

F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...

Passive income investors looking to get paid to navigate a more turbulent stock market should look to the many dividend ...